As of the latest Form 4 filed Jul 7, 2026.
What Pelthos Therapeutics Inc. insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 18 most recent filings for PTHS.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-07 | 2026-07-02 | Friedberg Ezra M Director | SSale | −24.00 | $27.33 | $655.81 | Yes (planned) | Form 4 ↗ |
| 2026-07-07 | 2026-07-02 | Friedberg Ezra M, Director | SSale | −534.00 | $26.03 | $13.9K | Yes (planned) | Form 4 ↗ |
| 2026-07-07 | 2026-07-02 | Pauls Matthew Director | SSale | −94.00 | $27.36 | $2.57K | Yes (planned) | Form 4 ↗ |
| 2026-07-07 | 2026-07-02 | Pauls Matthew, Director | SSale | −692.00 | $26.00 | $18.0K | Yes (planned) | Form 4 ↗ |
| 2026-07-07 | 2026-07-02 | Greenleaf Peter Director | SSale | −85.00 | $27.27 | $2.32K | Yes (planned) | Form 4 ↗ |
| 2026-07-07 | 2026-07-02 | Greenleaf Peter, Director | SSale | −712.00 | $26.00 | $18.5K | Yes (planned) | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | Friedberg Ezra M Director | SSale | −59.00 | $27.94 | $1.65K | Yes (planned) | Form 4 ↗ |
| 2026-06-17 | 2026-06-15 | Friedberg Ezra M, Director | SSale | −224.00 | $27.12 | $6.08K | Yes (planned) | Form 4 ↗ |
| 2026-06-15 | 2026-06-11 | Davis Todd C Director | PPurchase | +503.00 | $28.73 | $14.4K | No | Form 4 ↗ |
| 2026-06-15 | 2026-06-11 | Davis Todd C, Director | PPurchase | +35.4K | $27.80 | $986K | No | Form 4 ↗ |
| 2026-04-06 | 2026-04-02 | Malamut Richard Director | SSale | −280.00 | $21.36 | $5.98K | Yes (planned) | Form 4 ↗ |
| 2026-04-06 | 2026-04-02 | Malamut Richard, Director | SSale | −310.00 | $20.51 | $6.36K | Yes (planned) | Form 4 ↗ |
| 2026-04-06 | 2026-04-02 | Friedberg Ezra M Director | SSale | −265.00 | $21.36 | $5.66K | Yes (planned) | Form 4 ↗ |
| 2026-04-06 | 2026-04-02 | Friedberg Ezra M, Director | SSale | −293.00 | $20.51 | $6.01K | Yes (planned) | Form 4 ↗ |
| 2026-04-06 | 2026-04-02 | Pauls Matthew Director | SSale | −371.00 | $21.36 | $7.93K | Yes (planned) | Form 4 ↗ |
| 2026-04-06 | 2026-04-02 | Pauls Matthew, Director | SSale | −415.00 | $20.52 | $8.51K | Yes (planned) | Form 4 ↗ |
| 2026-04-06 | 2026-04-02 | Greenleaf Peter Director | SSale | −377.00 | $21.36 | $8.05K | Yes (planned) | Form 4 ↗ |
| 2026-04-06 | 2026-04-02 | Greenleaf Peter, Director | SSale | −420.00 | $20.52 | $8.62K | Yes (planned) | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also PTHS’s full analysis or the market-wide insider trading feed. The tabs above jump to PTHS’s other SEC data.
Source: SEC Form 4 filings for PTHS, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.